Patents by Inventor Jin-Chen Yu

Jin-Chen Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of anti-OX40 antibody in treatment of tumor or cancer
    Patent number: 12715930
    Abstract: The use of an anti-OX40 antibody or an antigen-binding fragment in the treatment of a tumor or cancer, is described. Also described is a treatment method of a tumor or cancer and includes administering to a patient in need an effective amount of an anti-OX40 antibody or an antigen-binding fragment. Kits including an anti-OX40 antibody or an antigen-binding fragment are also described.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: August 25, 2026
    Assignee: BIO-THERA SOLUTIONS, LTD.
    Inventors: Shizhong Liang, Binghui Liang, Jin-Chen Yu, Xiao Li, Shuqiang Song, Shengfeng Li
  • ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF
    Publication number: 20260144882
    Abstract: An anti-Nectin-4 antibody-drug conjugate and use thereof. The anti-Nectin-4 antibody and the antibody-drug conjugate thereof can be used for preventing and/or treating diseases.
    Type: Application
    Filed: July 13, 2023
    Publication date: May 28, 2026
    Inventors: Xingxing Mei, Cuiying Feng, Siqi Mai, Weijia Tang, Yao Qi, Jiaqi Zhou, Jin-Chen Yu, Shengfeng Li
  • ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
    Publication number: 20260008848
    Abstract: Disclosed herein are an anti-Nectin-4 antibody, an antibody-drug conjugate thereof, and use thereof. The anti-Nectin-4 antibody and the antibody-drug conjugate thereof can be used for treating a disease.
    Type: Application
    Filed: July 13, 2023
    Publication date: January 8, 2026
    Inventors: Xingxing MEI, Cuiying FENG, Weijia TANG, Yao QI, Hui ZHANG, Junyou CHEN, Zhiwei WANG, Xianming HUANG, Jin-Chen YU, Shengfeng LI
  • ANTI-NECTIN-4 ANTIBODY AND USE THEREOF
    Publication number: 20250388667
    Abstract: Provided are an anti-Nectin-4 antibody and the use thereof. The anti-Nectin-4 antibody or antigen-binding fragment can specifically bind to Nectin-4 and has high affinity and strong endocytosis capacity, and therefore can be used for diagnosis, prevention, and/or treatment of tumors (comprising cancers and benign tumors).
    Type: Application
    Filed: July 13, 2023
    Publication date: December 25, 2025
    Inventors: Xingxing Mei, Cuiying Feng, Weijia Tang, Hui Zhang, Junyou Chen, Zhiwei Wang, Xianming Huang, Jin-Chen Yu, Shengfeng Li
  • METHOD FOR TREATING SOLID TUMOR
    Publication number: 20250381283
    Abstract: The disclosed relates to the field of pharmaceutical therapeutic methods. Disclosed is a method for treating a solid tumor. The methods disclosed include treating solid tumors with antibody drug conjugate. The disclosed method includes administering to a patient with a solid tumor an effective amount of a TROP2-targeted antibody-drug conjugate.
    Type: Application
    Filed: June 27, 2023
    Publication date: December 18, 2025
    Inventors: Xingxing MEI, Xiao LI, Shuqiang SONG, Weijia TANG, Jin-Chen YU, Shengfeng LI
  • ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
    Publication number: 20250333498
    Abstract: Disclosed are an anti-CLDN18.2 antibody, and an antibody-drug conjugate and use thereof and relate to the field of biomedicine. In some embodiments, the antibody-drug conjugate is a compound represented by Formula I or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof. The anti-CLDN18.2 antibody and the antibody-drug conjugate can be used for treating diseases associated with CLDN18.2 expression.
    Type: Application
    Filed: May 31, 2023
    Publication date: October 30, 2025
    Inventors: Cuizhen XIAO, Chao QIN, Siqi MAI, Jin-Chen YU, Shengfeng LI
  • ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF
    Publication number: 20250262316
    Abstract: The present invention discloses an antibody-drug conjugate, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate and the pharmaceutical composition in the manufacture of a drug for treating and/or preventing a disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: August 21, 2025
    Inventors: Weijia TANG, Xuekang QI, Xin ZHOU, Hui YAN, Shuoxu LI, Jianjun FAN, Siqi MAI, Jin-chen YU, Shengfeng LI
  • METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR
    Publication number: 20250249114
    Abstract: Disclosed is a method for treating a HER2-positive solid tumor, which includes administering to a patient with a HER2-positive solid tumor an effective amount of an antibody-drug conjugate. The method also includes administering to a patient with a HER2-positive solid tumor an effective amount of an antibody-drug conjugate and another HER2-targeted antibody.
    Type: Application
    Filed: April 11, 2023
    Publication date: August 7, 2025
    Inventors: Weijia TANG, Shuqiang SONG, Xingxing MEI, Chuanqi CHAO, Jin-Chen YU, Shengfeng LI
  • Anti-TIGIT immunosuppressant and application thereof
    Patent number: 12371491
    Abstract: The present invention provides an anti-TIGIT immunosuppressant and use thereof. The immunosuppressant can bind to the extracellular region of human TIGIT, and can be used for treating diseases such as a cancer.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: July 29, 2025
    Assignee: Bio-Thera Solutions, Ltd.
    Inventors: Junjie Huang, Xiaoyun Wu, Zhenqian Xu, Shide Liang, Shengfeng Li, Jin-Chen Yu, Xianming Huang
  • ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
    Publication number: 20250059274
    Abstract: Disclosed is an antibody that specifically recognizes and binds to folate receptor ?, also referred to as anti-folate receptor a antibody or anti-FR? antibody. Also disclosed is an antibody-drug conjugate of the anti-FR? antibody. Disclosed are uses of the anti-FR? antibody and the antibody-drug conjugate in the treatment of diseases related to FR? expression.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 20, 2025
    Inventors: Weijia TANG, Siqi MAI, Xin ZHOU, Hui YAN, Shuoxu LI, Jianjun FAN, Jingyi SHEN, Shide LIANG, Jin-Chen YU, Shengfeng LI
  • USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES
    Publication number: 20250051450
    Abstract: The present invention discloses use of an anti-PD-L1/CD47 bispecific antibody in the treatment of a disease. A treatment method comprises administering to a patient in need thereof an effective amount of an anti-PD-L1/CD47 bispecific antibody or an antigen-binding fragment.
    Type: Application
    Filed: August 5, 2022
    Publication date: February 13, 2025
    Applicant: BIO-THERA SOLUTIONS, LTD.
    Inventors: Yifan Chen, Ziyi Fu, Qiulian Liang, Jin-Chen Yu, Shengfeng Li
  • ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF
    Publication number: 20240400690
    Abstract: Disclosed is an anti-B7-H3 antibody and application of an anti-B7-H3 antibody. The anti-B7-H3 antibody or an antigen-binding fragment can specifically bind to B7-H3. The anti-B7-H3 antibody or an antigen-binding fragment has high affinity and strong internalization capability, and can be used for the diagnosis and/or treatment of tumors (including cancers and benign tumors).
    Type: Application
    Filed: September 29, 2022
    Publication date: December 5, 2024
    Inventors: Huafei SU, Yuting ZHONG, Jinchan LIANG, Shide LIANG, Jin-chen YU, Shengfeng LI
  • DRUG CONJUGATE AND USE THEREOF
    Publication number: 20240269315
    Abstract: A drug conjugate, such as an antibody drug conjugate, and the use thereof, belonging to the field of biomedicine. In some embodiments, the drug conjugate is a compound of Formula I or a pharmaceutically acceptable salt or a solvate thereof, and can be used for treating cancers, autoimmune diseases, inflammatory diseases or infectious diseases.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 15, 2024
    Inventors: Weijia TANG, Xin ZHOU, Xingxing MEI, Hui YAN, Shuoxu LI, Jianjun FAN, Xuekang QI, Jin-Chen YU, Shengfeng LI
  • ANTI-CLDN18.2 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240092892
    Abstract: The present invention relates to the field of bio-pharmaceuticals and provides an anti-CLDN18.2 antibody. Related preparation methods and related uses are described. The antibody of the present invention or related an antigen-binding fragment can specifically bind to CLDN18.2 with a strong binding capacity. After humanization, the antibody or the antigen-binding fragment has a strong ADCC effect and CDC activity and has good pharmaceutical prospects.
    Type: Application
    Filed: December 29, 2021
    Publication date: March 21, 2024
    Inventors: Chao QIN, Cuizhen XIAO, Jin-Chen YU, Shengfeng LI
  • BISPECIFIC ANTIBODY AND USE THEREOF
    Publication number: 20240067728
    Abstract: The present invention provides a bispecific antibody and use thereof, and the bispecific antibody or an antigen-binding fragment of the present invention can bind to two or more antigens or two or more epitopes of a same antigen. The antibody or the antigen-binding fragment of the present invention can be used to treat a variety of diseases, such as inflammatory diseases, autoimmune diseases, cancers or spinal cord injury, and can also be used for diagnosis and prognosis of related diseases.
    Type: Application
    Filed: November 5, 2021
    Publication date: February 29, 2024
    Inventors: Yifan CHEN, Qiulian LIANG, Shujun PEI, Jin-Chen YU, Shengfeng LI
  • USE OF ANTI-PD-1 ANTIBODY IN COMBINATION THERAPY
    Publication number: 20240002511
    Abstract: Disclosed are anti-PD-1 antibodies and use of an anti-PD-1 antibody in a combination therapy. Treatment methods are disclosed and include administering to a patient in need an effective amount of an anti-PD-1 antibody and a therapeutic agent. Methods for treating a tumor or cancer using anti-PD-1 antibody and a therapeutic agent are disclosed.
    Type: Application
    Filed: October 9, 2021
    Publication date: January 4, 2024
    Inventors: Haitao YUE, Shujun PEI, Ziqi SU, Weijia TANG, Jin-Chen YU, Shengfeng LI
  • USE OF ANTI-OX40 ANTIBODY IN TREATMENT OF TUMOR OR CANCER
    Publication number: 20230416386
    Abstract: The use of an anti-OX40 antibody or an antigen-binding fragment in the treatment of a tumor or cancer, is described. Also described is a treatment method of a tumor or cancer and includes administering to a patient in need an effective amount of an anti-OX40 antibody or an antigen-binding fragment. Kits including an anti-OX40 antibody or an antigen-binding fragment are also described.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 28, 2023
    Applicant: Bio-Thera Solutions, Ltd.
    Inventors: Shizhong LIANG, Binghui LIANG, Jin-Chen YU, Xiao LI, Shuqiang SONG, Shengfeng LI
  • ANTI-CD20 ANTIBODY FORMULATION AND USE OF ANTI-CD20 ANTIBODY FOR TREATMENT OF CD20 POSITIVE DISEASES
    Publication number: 20230338526
    Abstract: Disclosed are anti-CD20 antibody formulations and use of anti-CD20 antibodies for the treatment of CD20 positive diseases, such as methods of using anti-CD20 antibodies for treating CD20 positive diseases, such as neuromyelitis optica spectrum disorders (NMOSD), non-Hodgkin's lymphoma (NHL), multiple sclerosis (MS), immune thrombocytopenia (ITP), rheumatoid arthritis (RA), Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), lupus nephritis, systemic lupus erythematosus and chronic lymphocytic leukemia (CLL).
    Type: Application
    Filed: October 12, 2020
    Publication date: October 26, 2023
    Inventors: Yanyu CHEN, Yong WU, Yuanqing ZHOU, Chao QIN, Cuizhen XIAO, Zhihao WU, Dandan HUANG, Yujie LIU, Shengwu WANG, Cuihua LIU, Yunpeng QI, Jin-Chen YU, Li ZHANG, Shengfeng LI
  • ANTI-CD47 ANTIBODY AND USE THEREOF
    Publication number: 20230303711
    Abstract: CD47 antibodies and use thereof are disclosed, particularly to monoclonal antibodies that recognize CD47, and more particularly to CD47 antibodies that do not cause significant levels of hemagglutination, red blood cell reduction and platelet reduction, and to a method for preparing these antibodies and use of these monoclonal antibodies in the manufacture of medicaments for treating cancer or infection.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 28, 2023
    Inventors: Xianqin LIU, Jingyi SHEN, Weijia TANG, Jin-Chen YU, Shengfeng LI
  • ANTI-PD-L1 ANTIBODY AND USE THEREOF
    Publication number: 20230287126
    Abstract: Disclosed are anti-PD-L1 antibodies and use of anti-PD-1 antibodies. The antibody or the antigen-binding fragment can specifically bind to PD-L1 and block the interaction between PD-1 and PD-L1. The antibody or the antigen-binding fragment can help the immune system to clear tumor cells, and can also be used for the diagnosis and prognosis of a tumor or a cancer.
    Type: Application
    Filed: August 6, 2021
    Publication date: September 14, 2023
    Inventors: Yifan CHEN, Qiulian LIANG, Jin-Chen YU, Shengfeng LI